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Background: This is a first-in-human study to determine the efficacy and tolerability of a new method of treating
glaucoma using a low-power, low-frequency, focused therapeutic ultrasound for glaucoma (TUG) device designed
to trigger an inflammatory reaction in the anterior chamber angle and trabecular meshwork to enhance outflow.
The use of the device is anticipated for mild or moderate open-angle glaucoma as an enhancement to outflow.
Methods: In a two-branch clinical trial, a total of 26 primary open-angle glaucoma patients underwent a procedure
consisting of the external application of the TUG device. In branch 1, nine of these patients were naïve to
pharmaceutical treatment or had been off of medication for over 6 months. In branch 2, 17 patients were
treated after a medication washout period. All patients in the study were followed for 12 months.
Results: In branch 1, there was a decrease in intraocular pressure averaging over 20% lasting at least a year in
74% of the eyes with non-normotensive open-angle glaucoma. In branch 2, an average of two visits while on
medication provided the comparison intraocular pressure (IOP) to the effect of the TUG treatment after washout.
It was seen that the intraocular pressure over the year post-treatment was equal to or better than the pharmaceutical
control in close to 80% of measurements.
Conclusion: A novel device for lowering intraocular pressure is described with a potential for adding to our
armamentarium for treating glaucoma. This is a small cohort study which indicates beneficial trends.
Trial registration number: The study was a registered clinical trial, #ISRCTN50904302.
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Open-angle glaucoma is a worldwide problem for which
newer, portable, low-cost, and effective treatments are
needed. Glaucoma affects approximately 3 million
people in the United States (source: preventblindness.
org—Prevent Blindness America) and 70 million world-
wide (source: glaucoma.org—Glaucoma Research Foun-
dation). It is expected that the increasing age of our
population will significantly increase the number of
people with this blinding disease. The present methods
used to treat glaucoma have significant drawbacks.* Correspondence: dschwartz@eyesonix.com
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unless otherwise stated.Pharmaceutical agents must depend on compliance,
often have side effects, and may interfere with other
medications required by the patient. The use of lasers
such as argon or selective laser trabeculoplasty offers a
useful alternative to many of the problems inherent with
pharmaceutical agents. However, these instruments re-
quire a slit lamp biomicroscope apparatus for viewing
the trabecular meshwork and a contact lens system for
application of the energy for such treatment.
Cataract surgery lowers intraocular pressure in pa-
tients with coexisting glaucoma [1-6]. The basis for this
effect may be due to both anatomic and biochemical
changes in the area of the trabecular meshwork since
observations have suggested that the use of ultrasound
in the eye may result in a decrease in pressure [7]. The
association of the decrease in pressure with cataractal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mulsification (ultrasound) became prevalent. The finding
that there is a decrease in the intraocular pressure (IOP)
after phacoemulsification has often been attributed to
an increase in the opening of the angle. This is certainly
true with narrow-angle glaucoma, but recent studies have
revealed no correlation between the change in chamber
depth and the IOP decrease with open-angle glaucoma
whereas the decrease is correlated with the pre-treatment
IOP [8-11]. In addition, reports of cataract surgery per-
formed with an intracapsular lens extraction did not indi-
cate a decrease in IOP. Intracapsular cataract surgery did
not involve the use of ultrasound. Radius et al. reported
that after the intracapsular cataract surgery, there was a
slight increase in the IOP [12].
A prototype instrument hand piece (see Figure 1) was
designed and built to produce low-frequency ultrasound
of 40 kHz. This frequency is the same as that of a typical
cataract surgery ultrasound. Although the frequency is the
same, the energy from the bubbles created by phacoemul-
sification can create cavitation with a temperature of over
7,000°C; the therapeutic ultrasound for glaucoma (TUG)
treatment power of less than 2 W/cm2 only allows a
temperature within the focal area to reach 45°C [13,14].
The instrument was developed for the external applicationFigure 1 A prototype TUG instrument hand piece.of ultrasound with the purpose of decreasing the intraocu-
lar pressure. We hypothesized that the application of low-
power and low-frequency focused ultrasound energy to
the trabecular meshwork could result in the lowering of
intraocular pressure by triggering a similar cytokine cas-
cade to that triggered by SLT laser. To verify the hypoth-
esis, we designed a prospective study.
Methods
The author confirms that (1) the research followed the
tenets of the Declaration of Helsinki, (2) informed con-
sent was obtained, (3) the research was approved by the
institutional review board to allow clinical studies (on
the basis of previous animal studies supporting a non-
significant risk classification), and (4) power analysis was
performed to justify the number of patients enrolled in
the study.
Device development
Prior to the use of the instrument, a power determin-
ation was performed with in vitro and in vivo animal
studies based on a temperature elevation of approxi-
mately 6°C. This temperature elevation was just below
that which causes pain and cell necrosis [15-17]. It was
found that with external application of the TUG device
of approximately 3 W of power/cm2 to the hand piece,
the temperature increased and then stabilized at ap-
proximately 43°C, when measured by a “K type” micro-
thermocouple positioned 0.5 mm below the surface of a
pig eye at the limbus using an Omega HH508 digital
thermometer. The instrument was developed and tested
with this microthermocouple to determine the power re-
quired to raise the temperature by 7° from baseline.
Testing was then repeated with pig eyes raised to a basal
temperature of 36.5°C by water bath to determine the
power to raise the temperature to 43°C to 44°C and
maintain this steady-state increased temperature.
In vivo work on the animal model at power settings
above 4 W/cm2 resulted in a large corneal inflammatory
reaction. Further in vivo studies therefore used only
power settings below this level. A point was then chosen
on the sclera side with 0.5 mm of clearance from the lim-
bus for this study.
Study description
In early clinical work, the first two series TUG.1 and
TUG.2 (not published) were conducted to determine the
tolerability (TUG.1) and to refine the parameters (TUG.2)
for treatment. The presently reported study (TUG.3) was
a prospective controlled study using the ultrasound in-
strument in the manner which optimized the intraocular
pressure-lowering effect.
This study was funded by EyeSonix Incorporated and
followed a protocol approved by Western Institutional
Figure 2 The investigator is performing a glaucoma procedure
with the TUG device.
Schwartz et al. Journal of Therapeutic Ultrasound 2014, 2:15 Page 3 of 11
http://www.jtultrasound.com/content/2/1/15Review Board (WIRB). The study was conducted at
one site in the Long Beach Eye Care Associates of-
fices. Health Insurance Portability and Accountability
Act (HIPPA)-compliant informed consent was approved by
WIRB. Each patient who participated in the study (or a des-
ignated family member) gave written consent. The study
was a registered clinical trial, #ISRCTN50904302.
Patient selection
Recruitment was conducted among glaucoma patients
seen at the study site.
The eligibility criteria were twofold:
1. Patients with open-angle glaucoma and without
medical or laser treatment for at least 6 months, or
2. Patients presently on pharmaceutical treatment for
glaucoma.
The exclusion criteria included both previous inva-
sive glaucoma surgery and an inability to comply with
follow-up visits. Treatment-naïve patients were offered
the option of pharmaceutical agents or laser (always
in this order) and also the option of being part of the
study.
Randomization and treatment protocol
Patients with symmetric IOP were randomized by a coin
flip as to the eye selected for the TUG treatment. If there
was a significantly higher IOP in one eye, this eye was
selected for the TUG treatment.
If patients were presently on pharmaceutical agents, a
bilateral washout period was performed. Prostaglandin
analog medications were washed out for 1 month. Other
agents were washed out for 1 week.
The treatment was performed after a measurement of
the IOP was taken, and an ocular examination was con-
ducted to determine the baseline IOP. The baseline IOP
was an average of the two IOP measurements prior to
the TUG treatment. In addition, an evaluation was per-
formed to characterize any baseline signs of inflamma-
tion. The following steps were performed during the
surgery illustrated in Figure 2. A drop of tetracaine was
applied. The patient was then placed in the supine pos-
ition. A lid speculum was used for exposure. A marking
pen was then used on the sclera to mark four equally
spaced quadrants at the limbus. The eye was then cov-
ered with lidocaine 3.5% gel (Akorn). This served as the
necessary transmission gel, an added anesthetic. Add-
itionally, it maintained corneal moisture. A function gen-
erator (Tektronix AFG3101 Single Channel Arbitrary/
Function Generator, calibrated in October of 2008) was
then tuned to generate the proper power and frequency.
This was fed by the single-channel output to a power
amplifier (E&J RF Power Amplifier, Model #2100 L,Serial #1045). The “EyeSonix” hand piece of 40 kHz was
then attached. The treatment was performed once the
correct power output with zero reflectance was deter-
mined by tuning the frequency.
A tip cover was then put over the hand piece. Next,
the tip was placed sequentially at the treatment sites.
The application was at a point 0.5 mm on the scleral
side of the limbus. Applications were 45 s in duration at
each clock hour position for 12 clock hours. The four
previously placed marks allowed for an equal positioning
of the spots of three per quadrant. Throughout the pro-
cedure, the power output was monitored and adjusted to
maintain the correct delivery of energy to the hand
piece. The intraocular pressure was measured 1 h after
the treatment as a safety precaution, since after laser tra-
beculoplasty there is a small chance of a pressure spike
after the treatment. No significant post-treatment pressure
elevations were seen. Post-treatment, the patients received
Nevanac (nepafenac ophthalmic suspension) 0.1% three
times a day for 1 day. This non-steroidal medication was
used if there were symptoms of inflammatory response:
soreness, photophobia, or signs of inflammation; the treat-
ment continued until the symptoms and signs resolved.
Steroids, although more powerful, were avoided as the
post-inflammatory response was desired. The patients
were seen 14 times post-surgically: on the following day,
1 week later, and after that once a month for 12 months.
The measurements of IOP were not taken in 17 patients
for a total of 47 missed follow-up visits to the investiga-
tor’s office. Two patients were lost to the follow-up visits
after the 6-month appointment, and two dropped out
after being in the study for 10 months.
Results of the treatment were tabulated at each follow-
up visit into two general categories. The first category
was that of the intraocular pressure. The pre-treatment
(or baseline) IOP reading was an average of the two
most recent readings prior to the washout. These were
Goldmann applanation measurements. Post-treatment
readings of both eyes were obtained by the technician
Figure 3 Average IOP decrease (in mmHg) from the baseline in
medication-free patients in treated v. control eyes, N = 9.
Figure 4 Average percent IOP decrease from the baseline in
medication-free patients in treated v. control eyes, N = 9.
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tonometry was performed in two different methods.
“Tonopen” (Tono-Pen XL Medtronic) measurements
were taken by well-trained technicians with at least four
separate readings. These readings were then averaged.
After the tonopen measurements were recorded, the tech-
nician performed Goldmann applanation tonometry. A sec-
ond Goldmann applanation tonometry was performed by
the investigator. The two Goldman readings were then av-
eraged with the average of the tonopen readings; therefore,
the Goldman readings were weighted at 66% of the average
for the single overall reported average. The Goldmann
tonometer was calibrated at least once a week.
The second category was of an analysis of the inflam-
matory reaction from the treatment. This evaluation in-
cluded the subjective symptoms of irritation, discomfort,
and pain and an objective slit lamp evaluation for signs
of conjunctival injection and signs of anterior chamber
cells and flare. Each of the parameters was graded on a 0
to 4 scale (minimal to maximal presence). The subjective
symptoms were elicited by staff technicians and verified
by the investigator and were always asked in the same
manner. The slit lamp evaluation was performed by the
investigator. Each of the markers was characterized on a
scale of 0 to 4 with 0 being minimally present and 4 the
worst possible. These subjective responses were obtained
by assistants and verified by the investigator. The signs
were observed at the same slit lamp at each visit. The
conjunctival injection was observed under low magnifi-
cation in a low-light room condition whereas cell and
flare were evaluated with high power in a dark room.
Results
Intraocular pressure
The IOP was analyzed separately in medication-free pa-
tients, in medication-free non-normotensive glaucoma pa-
tients, and in those who were previously on medication.
Medication-free patients
For the nine patients, the mean age was 73.3 ± 9.0 years
(min = 62 years, max = 89 years). Eight patients were
Caucasian and one was African-American. One patient
was female and eight patients were male. Two patients
had primary open-angle glaucoma, four had normoten-
sive glaucoma, and one had pigmentary glaucoma. In
Figure 3, the graph of an average IOP decrease from the
baseline for the treatment and control groups is pre-
sented. In both groups, there is an overall downward
trend in average IOP, with the control group profile
remaining above but shadowing that of the treatment
group.
The average percent decrease in the IOP from the
baseline value is represented in Figure 4. The trend line
from the time of treatment over the 12-month periodreveals a decrease in pressure in both the treated and
the contralateral eye which persists throughout the dur-
ation of follow-up. Note that for these medication-free
patients, the average percent IOP reduction from the
baseline is over 20% 1 year post-treatment in either eye.
Medication-free non-normotensive glaucoma patients
When reviewing the findings, it became apparent that
the decrease in intraocular pressure was less evident
with those whose pre-treatment pressure was below
19.5 mmHg. Thus, the analysis was redone without the
four normotensive glaucoma patients in order to obtain
further perspective in considering the treatment on pa-
tients with intraocular pressures of 20 or greater.
For the remaining five patients, the mean age was
71.8 ± 11.8 years (min = 62 years, max = 89 years). All pa-
tients were Caucasian males. Four patients had primary
open-angle glaucoma and one had pigmentary glaucoma.
Of these five patients, one missed two follow-up visits,
and thus, the data were unavailable in the two cases.
Figures 5 and 6 show, respectively, the average IOP de-
crease and average percent IOP decrease from the base-
line for this group of patients. On both graphs, larger
Figure 5 Average IOP decrease (in mmHg) from the baseline in
medication-free non-normotensive glaucoma patients in
treated v. control eyes, N = 5.
Figure 7 Individual profile for a medication-free non-normotensive
glaucoma patient: IOP measurements in treated v. control eyes
prior to the TUG treatment and during the study follow-up.
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ular pressure are observed in the medication-free patient
group (cf. Figures 3 and 4). The average percent IOP de-
crease from the pre-treatment value approaches 25% as
opposed to 20% for all medication-free patients.
Example of a medication-free non-normotensive glaucoma
patient
Figure 7 presents an IOP profile for a non-normotensive
glaucoma study participant. This person had been a
patient in our practice for 3 years with normal pres-
sures and cup disc ratios. He was seen for routine exam-
ination in 2010 and found to have increased optic
nerve head cupping and an elevated IOP of 32 mmHg
by Goldmann applanation tonometry. He was then
given options for treatment and chose the TUG study.
The IOP measurements were taken at pre-treatment,
1 day and 1 week post-surgery, and then every month for
1 year. His central corneal thickness (CCT) measurements
were 526 and 530 μm in the treated and the control eye,
respectively.Figure 6 Average percent IOP decrease from the baseline in
medication-free non-normotensive glaucoma patients in
treated v. control eyes, N = 5.Note that the control eye exhibits a similar behavior in
terms of the IOP measurements to the treated eye.
Noteworthy is the length of this effect in both eyes after
only one treatment in one eye for this patient.
Medication washout patients
The mean age of the 17 patients was 73.1 ± 13.2 years
(min = 51 years, max = 92 years). Fourteen patients were
Caucasian, one African-American, and one Hispanic. Six
females and 11 males were treated. Eight patients had pri-
mary open-angle glaucoma, seven had normotensive glau-
coma, and two had pigmentary glaucoma. Twelve patients
missed a follow-up, but came back for subsequent visits.
Two patients dropped out after being in the study for
6 months, and two dropped out after 10 months.
In this group of 17 medication washout patients, three
patients had a second TUG treatment within 1 year.
Such retreatments were performed if the intraocular pres-
sure approached the washout pressure. These retreat-
ments occurred at either the fifth or the sixth month
post-initial TUG treatment. Also in this group of pa-
tients, four of the 17 had a reintroduction of medication.
It should be noted that the washout of the medication was
for both eyes. One of the patients had a resumption of
medication in the control eye, but not in the treated eye.
Of the group that went back on medication, one patient
used the medication for only 1 month and found the
medication again led to unacceptable irritation. She then
was one of the four who had a second TUG treatment.
The baseline IOP value for these patients was an aver-
age of the IOP measurements for two visits prior to the
medication washout period. The effect of the TUG treat-
ment in the IOP reduction was compared to the IOP on
the pharmaceutical regimen.
Figure 8 shows the average change in IOP from the
baseline after the initial TUG treatment. Where the graph
is above zero, the post-TUG treatment IOP was higher,
Figure 8 Average IOP difference from pharmaceutical control
in washout patients in treated v. control eyes, N = 17.
Figure 10 Percent of patients in the medication washout group
(N = 17) whose IOP change from the baseline value was within
10% or below the pharmaceutical control: treated v. control
eyes, N = 17.
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the two IOP measurements deviate very little from each
other always remaining within ±2 mmHg.
Figure 9 represents the same results as in Figure 8 but
in terms of the average percent of change in IOP from
the patient’s pharmaceutical regimen. The positive values
on the graph indicate that the post-TUG treatment IOP
exceeds that of the pharmaceutical regimen.
To analyze the number of patients who retained clin-
ical control of pressure after washout, a connected graph
of percent of medication washout patients with IOP
change from baseline of at most 10% is constructed (see
Figure 10).
Examples of medication washout patients
Figure 11 demonstrates an historical perspective of IOP
measurements in both eyes across the visits for a patient
in the medication washout group. This patient was among
the 13 (74%) patients who needed only a single TUG treat-
ment to last 1 year. In the past, he had been on latano-
prost which controlled his IOP to approximately 16. HeFigure 9 Average percentage change in IOP from the
pharmaceutical regimen.had a washout of this medication. At the end of the 1-year
period, he was off medication in both eyes with an IOP
around 16 mmHg. Even longer follow-up shows his IOP
to be maintained at a significant decrease from baseline
and even from pharmaceutical control.
The next graph (Figure 12) illustrates an IOP historical
perspective for a patient who was compelled to return to
medication with additive effect and later chose to have a
TUG retreatment which showed an enhanced effect
from the second treatment over the original. This pa-
tient was on latanoprost and then changed to Combigan
as a result of side effects of the latanoprost. Her IOP on
medication was 21 mmHg. She had a 1-week washout of
the Combigan with a resultant IOP of 23 mmHg. Her
TUG treatment led to a decrease in IOP to 17 mmHg,
but it gradually increased to 23 mmHg over a 5-month
period of time. She was offered the option of returning
to medication. She was reintroduced to medication with
a substantial decrease to 12.5 mmHg. But she again was
bothered by the side effects of Combigan and elected to
have a second TUG treatment after washout. The sec-
ond TUG treatment was performed, and after 7 months
post-TUG #2 (1 year after TUG#1), the IOP was 15 mmHg
without medication.
The first subject to have bilateral treatment is illus-
trated (Figure 13). His pressure gradually elevated over
time after SLT laser. He elected to have TUG rather than
a repeat SLT or initiation of pharmaceutical agents.
After coin flip, the first treated was the right eye (OD).
There was a profound effect on this treated eye. The
non-treated eye appeared to have a modest effect. After
7 months, the non-treated eye returned to baseline. At
this time, the left eye (OS) was treated. The graph shows
that for close to 3 years after the treatment of the second
eye, the intraocular pressures are significantly lower than
baseline in both eyes.
Figure 11 Historical perspective for a medication washout patient: IOP measurements in both eyes prior to the TUG treatment and
during the study follow-up.
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The intraocular pressure was measured at a time approxi-
mately 2 h after the treatment to look for any possible pressure
spikes. No pressure spikes were found in the patients treated.
The tolerability of the treatment with the TUG device
was evaluated at each visit. Patients were queried about
three markers of patient symptoms: irritation, discomfort,
and pain. Similarly, there were three findings which we as-
sociated with signs of inflammatory response: conjunctival
injection, anterior chamber cells, and flare.
The values of symptoms scores were as follows:
1. Irritation scores ranged between 1 and 2.5 in three
patients at the 1-day visit. One week after the
treatment, irritation was gone.Figure 12 Historical perspective for a medication washout patient wh
IOP measurements in both eyes prior to the first TUG treatment and2. Discomfort was present in four patients at the 1-day
visit. One had a score of 2, and three were at 1. At
1 week post-treatment, one patient was at 1, one at
1.5, and the rest were at 0. Afterwards, this symptom
has disappeared.
3. Pain was experienced by one patient at the level
of 2 at the 1-day visit. Besides this instance, pain
was absent for each and every patient at each and
every visit.
The values of signs scores are listed below:
1. Injection of the conjunctiva was a frequent but
short-lived finding. At the first visit, 1 day after
the treatment, it was found in 24 of the 26 patients.o resumed medication and underwent a second TUG treatment:
during the study follow-up.
Figure 13 The first subject to undergo the TUG treatment in each eye. The second eye was treated 7 months after the first eye when the
intraocular pressure in that eye had increased to the original baseline.
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seven were at 2. There were five at 1.5, seven at 1, and
the other three scored 0.5. By the 1-week visit, only
eight had any such finding: two at 0.5 and six at 1.
This sign was not apparent afterwards.
2. Cells in the aqueous humor were not observed in
any of the patients at any visit.
3. Flare was observed in the treated eye of nine patients
on the first day. In five patients, the score was 0.5, and
the other four had a score of 1. At the 1-week visit, a
flare score of 0.5 was measured in a single patient. In
the other patients, this sign was absent.
In summary, there is a frequent finding of conjunctival
injection with a subjective feeling of irritation that fades
over several days. No symptom or sign reached the levelFigure 14 Average symptoms scores (irritation, discomfort, and pain)of 3 at any time. The more serious symptom of pain and
sign of cells in the aqueous humor were remarkable for
their absence at each and every visit including the first
day (with one exception of pain on day 1).
The average symptoms and signs scores are shown in
Figures 14 and 15, respectively. As can be seen on the
graphs, the minimal findings have dissipated by 1 month.
It is doubtful that new signs or symptoms will appear in
the longer follow-up.
From the graphs, the patients tolerated the procedure
quite comfortably with the only common comment of
mild irritation which was consistent with a mild to mod-
erate conjunctival injection. These typically resolved in a
few days in almost all cases without treatment. If the pa-
tient had these findings, Nevanac (nepafenac ophthalmic
suspension) was offered. Most patients declined to usein TUG patients over the duration of the study.
Figure 15 Average signs scores (injection, cells, and flare) in TUG patients over the duration of the study.
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warrant any pharmaceutical treatment.
Discussion
The armamentarium of treatment modalities for glaucoma
is increasing. At the present time, pharmaceutical agents
are typically the first line of treatment with the use of laser
seen as an adjunct method. A new method of decreasing
intraocular pressure is described. This is the initial study
to be reported using a low-frequency, low-power, focused
ultrasound for the treatment of glaucoma.
The mechanism of action has yet to be described fully,
but the design of the ultrasound was with the purpose of
creating a focal area of hyperthermia within the anterior
chamber angle. It was felt that such an effect could trig-
ger inflammatory cytokines analogous to the effect of
SLT laser. The finding of a concurrent decrease in the
intraocular pressure in the contralateral eye may support
this mechanism of action.
We hypothesized that ultrasound energy applied exter-
nally near the limbus may have at least three modes of
action all of which could trigger a decrease in the intra-
ocular pressure. None of these potential modes of action
are mutually exclusive, and other modes are certainly
possible.
Firstly, there may be a sonomechanical, or vibratory, ef-
fect transmitted to the trabecular meshwork, loosening
debris and flushing out blockages [18-24]. Work in Sweden
by Björn Svedbergh resulted in a patented device with
the expressed concept of shaking debris to loosen tra-
becular meshwork blockage (Ultrasound Probe—US
Patent 6162193, filing date Sep 15, 1997, issue date
Dec 19, 2000). This device utilized a fluid-filled chamber
with a membrane for applying non-focused ultrasound
transmission to the external eye.
A second mechanism, that of a localized hyperthermia,
may trigger heat shock proteins and potentially beneficial
cytokines. This would hypothetically be similar to acytokine response evoked by laser trabeculoplasty [25-33].
Specific cytokines have been demonstrated to lower
the IOP after both argon and selective laser trabecu-
loplasty and have also been found to be triggered by
ultrasound of a frequency similar to that used in pha-
coemulsification [34].
A third mode of effect may be an induction of cyto-
kines through integrins [35,36]. These receptors absorb
ultrasound energy and in turn induce cytokine activity
which may be beneficial in lowering the IOP.
Ultrasound energy applied externally to the eye has a
significant advantage compared with many other treat-
ment modalities in that it can be applied in a non-
invasive manner. Previous treatments to use ultrasound
to treat glaucoma have been directed more posteriorly
[37-42]. Coleman et al. revealed that high-intensity fo-
cused ultrasound (HIFU) led to an ablation of the ciliary
body and a subsequent thinning of the sclera. The energy
was directed from the outside of the eye towards the cil-
iary body with an attempt to ablate the tissue and thereby
decrease aqueous production. This high-powered ultra-
sound had an additional effect in leading to a thinning of
the sclera overlying the ciliary body. The use of this ultra-
sound model was for intransigent glaucoma, and its use
fell from favor with the advent of other superior treatment
methods. Recently, another group (EyeTechCare of Lyon,
France) has reported an ultrasound device, “EyeOP1”,
used to coagulate the ciliary epithelium. This device uses a
single-treatment strategy with a circular tip with a mul-
tiple port array. These ports focus high-intensity ultra-
sound into the ciliary body to decrease aqueous inflow in
patients with refractory glaucoma [17].
In a single-center pilot study of a novel glaucoma treat-
ment technique (TUG), we found a significant decrease in
intraocular pressure. The effect on intraocular pressure in
the “naïve” group was significant with an average decrease
in the total group of almost 20% and almost 25% when
not including the normotensive glaucoma patients. The
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the higher baseline intraocular pressures. In over 74%, the
effect lasted for 1 year. A second treatment was offered if
the IOP rose to baseline. Subsequent TUG treatments
typically lasted far longer than the first treatment (beyond
the 1 year reported in this study).
In those subjects washed out of their pharmaceutical
glaucoma medication, the intraocular pressure measure-
ments after the TUG treatment were equal (within 10%)
to or even better (70% of the visits) than their pharma-
ceutical control for the year of the study.
The subjects tolerated the procedure well with only
minimal discomfort noted on the first day post-treatment.
There was typically a symptom of only a mild feeling of ir-
ritation and a slit lamp finding of mild to moderate con-
junctival hyperemia.
A method to treat glaucoma which reduces the issues
of pharmaceutical compliance, allergy, and side effects
and has the potential for portability could be a signifi-
cant contribution. It has even more potential for areas of
the third world where glaucoma is more prevalent and
treatment with medication and/or surgery is unavailable.
An updated prototype weighing less than 5 lbs with the
same characteristics as that used for this study has now
been produced and is in early multicenter clinical trials.Conclusion
This is a report of a first-in-human trial of a low-power,
low-frequency ultrasound instrument to treat open-angle
glaucoma. The findings are supportive of a well-tolerated
procedure with a significant decrease in intraocular pres-
sure. Further studies are needed for validation.
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